Melatonin Receptor Agonist — Hypnotic
Pregnancy: Insufficient data — avoid unless clearly necessary. Non-pharmacological sleep measures preferred in pregnancy.
Melatonin
Brand names: Circadin (2mg modified-release — licensed), Slenyto (paediatric), Various OTC preparations (unlicensed in UK)
Adult dose
Dose: Insomnia (adults ≥55 years — licensed indication for Circadin): 2mg at bedtime, 1–2h before sleep; take after food. Off-label (adults <55 years, shift work, jet lag): 0.5–5mg at bedtime.
Route: Oral
Frequency: Once nightly, 1–2 hours before bedtime
Max: 2mg OD (licensed Circadin); 10mg (off-label — higher doses not associated with proportionally greater benefit)
Circadin (2mg MR) is licensed only in adults ≥55 years for primary insomnia. Treatment should not exceed 13 weeks. Physiological replacement of endogenous melatonin — no dependence or withdrawal. Non-habit forming — preferred hypnotic in elderly and in patients where benzodiazepine dependence is a concern. Slenyto is licensed for paediatric insomnia associated with autism spectrum disorder (ASD) or Smith-Magenis syndrome.
Paediatric dose
Route: Oral
Frequency: Once nightly, 30–60 minutes before bedtime
Max: 10mg OD (Slenyto — ASD/SMS)
BNFc / NICE: Slenyto: ASD or Smith-Magenis syndrome (2–17 years): 1mg 30–60 min before bedtime; increase to 5mg then 10mg if needed. General paediatric insomnia: off-label use of melatonin 0.5–3mg is widespread — seek specialist paediatric sleep/psychiatry opinion. Not licensed for general insomnia in children under 18 years outside ASD/SMS.
Dose adjustments
Renal
No dose adjustment required.
Hepatic
Significant hepatic impairment: avoid — increased exposure due to reduced hepatic clearance (CYP1A2 metabolism).
Clinical pearls
- Timing is crucial: take 1–2h before desired sleep time — melatonin signals circadian rhythm shift rather than acting as a direct sedative; taking at the wrong time in the circadian cycle reduces efficacy
- No dependence — preferred over temazepam or zopiclone for long-term insomnia management in elderly or in patients with prior BDZ dependence
- Jet lag: take at local destination bedtime for 2–3 days to reset circadian rhythm; 0.5–3mg is adequate (higher doses not more effective for jet lag)
- Light exposure: advise patients to avoid bright screens and blue light 2h before bedtime — blue light suppresses endogenous melatonin production and counteracts the drug's effect
Contraindications
- Autoimmune diseases (theoretical — melatonin may stimulate immune function)
- Hypersensitivity to melatonin
Side effects
- Headache
- Somnolence (mild)
- Dizziness
- Nausea
- Irritability (morning residual — rare)
- No dependence or withdrawal
Interactions
- Fluvoxamine — strongly inhibits CYP1A2; increases melatonin levels 17-fold; avoid combination
- CYP1A2 inhibitors (ciprofloxacin, cimetidine) — increase melatonin levels; reduce dose
- Alcohol — may impair melatonin sleep-promoting effect and increase somnolence
- Warfarin — possible increased anticoagulant effect; monitor INR
Monitoring
- Sleep diary (subjective response)
- No specific blood monitoring required
- Duration of use (licensed indication for 13 weeks maximum in adults ≥55 years)
Reference: BNFc; BNF 90; NICE NG215 (Insomnia); NICE TA739 (Slenyto for ASD/SMS); Circadin SPC. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Modified Mallampati Classification · Airway Assessment
- PICU Delirium Assessment (pCAM-ICU) · Delirium Assessment
- Modified Early Warning Score (MEWS) · Early Warning
- Vasoactive-Inotropic Score (VIS) · Inotropic Support
- Modified Shock Index (MSI) · Haemodynamic Assessment
- Modified Sgarbossa's Criteria (Smith Modification) for MI in LBBB · ECG Interpretation
Pathways
- Acute Behavioural Disturbance / Rapid Tranquillisation · RCEM 2022; RCPsych 2022; NICE NG10
- Self-Harm Presentation · NICE NG225 (2022)
- Capacity Assessment (Mental Capacity Act) · MCA 2005; Code of Practice
- Acute Psychosis Management · NICE CG178 2014
- Depression Management · NICE CG90 2022
- Lithium Therapy Monitoring · NICE CG185 / BNF